Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

3.565 +0.065 (+1.86%)
Streaming Delayed Price Updated: 3:36 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
From Lantern Pharma Inc.
Via Business Wire
Which stocks have an unusual volume on Wednesday? ↗
Via Chartmill
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline With Multiple 2026 Milestones in View
Via Investor Brand Network
Topics Artificial Intelligence
Discover the top movers in Tuesday's pre-market session. ↗
Via Chartmill
News headline image
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Lantern Pharma Inc.
Via Business Wire
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
Via ACCESS Newswire
News headline image
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Clearance For STAR-001 Pediatric CNS Cancer Trial
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
From Lantern Pharma Inc.
Via Business Wire
News headline image
RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Fourth Quarter And Fiscal Year 2025 Results Webcast
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
Via ACCESS Newswire
News headline image
RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Present AI-Driven Neuro-Oncology Strategy at Glioblastoma Summit
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television
Via ACCESS Newswire
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Lantern Pharma Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Lantern Pharma Earnings Preview ↗
 
Via Benzinga
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.